Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors

Anindya Das, Avijit K. Adak, Kalyankumar Ponnapalli, Chien Hung Lin, Kai Cheng Hsu, Jinn Moon Yang, Tsu An Hsu, Chun Cheng Lin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The design of potent metabolically stable neuraminidase (NA) inhibitors represents an attractive approach for treating influenza virus infection. In this study, we describe the exploitation of the 150-cavity in the active site of group 1 NA for the design, synthesis, and in vitro evaluation of new triazole-containing N-acyl derivatives related to Zanamivir. Inhibition studies with influenza virus NAs of group 1 (H1N1) and group 2 (H3N2) revealed that several of them are good inhibitors, with IC50 values in the low nanomolar (2.3 nM–31 nM) range. Substituents that form stable van der Waals interaction with the 150-cavity residues play crucial roles in NA inhibition as demonstrated by the potency of 6a (H1N1 IC50 = 2.3 nM, and H3N2 IC50 = 2.9 nM). Docking studies indicated that the cyclohexane-substituted triazole ring extended toward the hydrophobic region in the active site of group 1 NA in open form. The high potency observed for inhibitor 6a may be attributable to the highly favorable hydrophobic interactions in this region.

Original languageEnglish
Pages (from-to)397-406
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Volume123
DOIs
Publication statusPublished - Nov 10 2016

Fingerprint

Zanamivir
Triazoles
Neuraminidase
Inhibitory Concentration 50
Orthomyxoviridae
Viruses
Catalytic Domain
Virus Diseases
Hydrophobic and Hydrophilic Interactions
Derivatives

Keywords

  • Influenza
  • Neuraminidase inhibitors
  • Triazole
  • Zanamivir

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors. / Das, Anindya; Adak, Avijit K.; Ponnapalli, Kalyankumar; Lin, Chien Hung; Hsu, Kai Cheng; Yang, Jinn Moon; Hsu, Tsu An; Lin, Chun Cheng.

In: European Journal of Medicinal Chemistry, Vol. 123, 10.11.2016, p. 397-406.

Research output: Contribution to journalArticle

Das, Anindya ; Adak, Avijit K. ; Ponnapalli, Kalyankumar ; Lin, Chien Hung ; Hsu, Kai Cheng ; Yang, Jinn Moon ; Hsu, Tsu An ; Lin, Chun Cheng. / Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors. In: European Journal of Medicinal Chemistry. 2016 ; Vol. 123. pp. 397-406.
@article{8fd2b15031db43baa5019f92f1497560,
title = "Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors",
abstract = "The design of potent metabolically stable neuraminidase (NA) inhibitors represents an attractive approach for treating influenza virus infection. In this study, we describe the exploitation of the 150-cavity in the active site of group 1 NA for the design, synthesis, and in vitro evaluation of new triazole-containing N-acyl derivatives related to Zanamivir. Inhibition studies with influenza virus NAs of group 1 (H1N1) and group 2 (H3N2) revealed that several of them are good inhibitors, with IC50 values in the low nanomolar (2.3 nM–31 nM) range. Substituents that form stable van der Waals interaction with the 150-cavity residues play crucial roles in NA inhibition as demonstrated by the potency of 6a (H1N1 IC50 = 2.3 nM, and H3N2 IC50 = 2.9 nM). Docking studies indicated that the cyclohexane-substituted triazole ring extended toward the hydrophobic region in the active site of group 1 NA in open form. The high potency observed for inhibitor 6a may be attributable to the highly favorable hydrophobic interactions in this region.",
keywords = "Influenza, Neuraminidase inhibitors, Triazole, Zanamivir",
author = "Anindya Das and Adak, {Avijit K.} and Kalyankumar Ponnapalli and Lin, {Chien Hung} and Hsu, {Kai Cheng} and Yang, {Jinn Moon} and Hsu, {Tsu An} and Lin, {Chun Cheng}",
year = "2016",
month = "11",
day = "10",
doi = "10.1016/j.ejmech.2016.07.064",
language = "English",
volume = "123",
pages = "397--406",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors

AU - Das, Anindya

AU - Adak, Avijit K.

AU - Ponnapalli, Kalyankumar

AU - Lin, Chien Hung

AU - Hsu, Kai Cheng

AU - Yang, Jinn Moon

AU - Hsu, Tsu An

AU - Lin, Chun Cheng

PY - 2016/11/10

Y1 - 2016/11/10

N2 - The design of potent metabolically stable neuraminidase (NA) inhibitors represents an attractive approach for treating influenza virus infection. In this study, we describe the exploitation of the 150-cavity in the active site of group 1 NA for the design, synthesis, and in vitro evaluation of new triazole-containing N-acyl derivatives related to Zanamivir. Inhibition studies with influenza virus NAs of group 1 (H1N1) and group 2 (H3N2) revealed that several of them are good inhibitors, with IC50 values in the low nanomolar (2.3 nM–31 nM) range. Substituents that form stable van der Waals interaction with the 150-cavity residues play crucial roles in NA inhibition as demonstrated by the potency of 6a (H1N1 IC50 = 2.3 nM, and H3N2 IC50 = 2.9 nM). Docking studies indicated that the cyclohexane-substituted triazole ring extended toward the hydrophobic region in the active site of group 1 NA in open form. The high potency observed for inhibitor 6a may be attributable to the highly favorable hydrophobic interactions in this region.

AB - The design of potent metabolically stable neuraminidase (NA) inhibitors represents an attractive approach for treating influenza virus infection. In this study, we describe the exploitation of the 150-cavity in the active site of group 1 NA for the design, synthesis, and in vitro evaluation of new triazole-containing N-acyl derivatives related to Zanamivir. Inhibition studies with influenza virus NAs of group 1 (H1N1) and group 2 (H3N2) revealed that several of them are good inhibitors, with IC50 values in the low nanomolar (2.3 nM–31 nM) range. Substituents that form stable van der Waals interaction with the 150-cavity residues play crucial roles in NA inhibition as demonstrated by the potency of 6a (H1N1 IC50 = 2.3 nM, and H3N2 IC50 = 2.9 nM). Docking studies indicated that the cyclohexane-substituted triazole ring extended toward the hydrophobic region in the active site of group 1 NA in open form. The high potency observed for inhibitor 6a may be attributable to the highly favorable hydrophobic interactions in this region.

KW - Influenza

KW - Neuraminidase inhibitors

KW - Triazole

KW - Zanamivir

UR - http://www.scopus.com/inward/record.url?scp=84979747918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979747918&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2016.07.064

DO - 10.1016/j.ejmech.2016.07.064

M3 - Article

C2 - 27487569

AN - SCOPUS:84979747918

VL - 123

SP - 397

EP - 406

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -